ArticleCancer immunology, immunotherapy : CII2024

Correction to: Efficacy and safety of anti‑PD‑1/PD‑L1‑based dual immunotherapies versus PD‑1/PD‑L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta‑analysis.

Yueying Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.